

Nahed El Kassar, M.D., MSc-Ph.D.

W: 301-827-8268

Email: nahed.elkassar@nih.gov

---

POSITIONS HELD

**Medical Officer / Associate Professor / Research Fellow / Transfusion Center Laboratory Co-Director / Attending Physician / Chief Resident**

SUMMARY OF EXPERTISE & SKILLS

Over 30 years of medical and clinical research expertise from clinical care responsibilities at several hospitals in France, to more recent critical role as a Medical officer at the NHLBI administering Clinical trials such as the “Clinical Trial of COVID-19 Convalescent Plasma of Outpatients” (C3PO)

M.D. in internal medicine, benign and malignant hematology, and transfusion. Masters and Ph.D. in Biology of blood cells. Fellowship in basic immunology and stem cell research at the National Cancer Institute

Supervisory experience as a co-director in HLA laboratory in Creteil-Paris (France)

Scientific oversight of systematic reviews and comparative effectiveness reports prepared for clinicians, patients, and policymakers

Managed and implemented U.S. Government strategies for complex clinical trials. Analyzed and/or developed strategies, policies and protocols in support of U.S. Government interests in national and international settings. Experience in managing sensitive situations. Strong technical written and verbal communication. Fluent in two foreign languages: French and Arabic; basic Spanish

SECURITY CLEARANCE

**Secret Clearance:** Issued by Health and Human Services/National Institutes of Health (NIH), November 2012 - Present

CURRENT RELEVANT CERTIFICATIONS

Contracting Officer Level II certification - *current*

Medical License (France) - *current*

Educational Commission for Foreign Medical Graduates certification - *current*

WORK EXPERIENCE

<b>MEDICAL OFFICER</b>	<b>March 2015 - Present</b>
------------------------	-----------------------------

*Blood Epidemiology and Clinical Therapeutics/Division of Blood Diseases and Resources at the National Heart, Lung and Blood Institute (NHLBI), NIH; Bethesda, MD*

- **Program Director** with a diverse grant portfolio that includes:

- Single and multi-sites (National and International) phase I to IV clinical trials and networks in Transfusion Medicine, Blood and marrow transplant, SCD, Thalassemia and other Hematology disorders. I work with the investigators on their protocol, regulatory documents and milestones, with focus on safety monitoring. Serve as the Contact DBDR program officer for the Single-Site Investigator-Initiated Clinical Trials (R61/R33 [PAR-19-328](#)) and organize all calls for new requests on >\$500k for clinical trials in transfusion and hematology.

- Technical, scientific and administrative input in the institute's effort for COVID-19 research. I was the PO of the multisite convalescent plasma trial (C3PO) (<https://siren.network/clinical-trials/c3po>) co-funded by BARDA and the NHLBI and run within the SIREN network. I have worked actively with the investigators at all steps of the clinical trial: finalizing the protocol, completing the regulatory requirements, accelerating enrollment, ensuring testing kits and convalescent plasma supplies, and developing ancillary studies. I have collaborated with BARDA, OWS, and NCATS on logistics, and harmonization and data sharing. Currently working on publishing the secondary data. <https://pubmed.ncbi.nlm.nih.gov/34407339/>

- Basic and translational research in the fields of Thrombosis, Myeloproliferative and Myelodysplastic syndromes, Graft Versus Host Disease, hematopoiesis, HIV and other immunology disorders

- **Evaluation and promotion of assigned scientific areas:**

Participate to the NIH COVID-19 research effort

- In addition to C3PO and the PASC task force effort, I co-initiated the NOSI supplements for early phase clinical trials in COVID-19 for NHLBI grantees [NOT-HL-20-782](#). I answered the applicant's inquiries and reviewed their proposals. I also reviewed the NOSI supplements on COVID-19 research (NOT-HL-20-757) basic research proposed by my grantees.

- Collaborated with NIAID, NCATS, OD and OWS on the organization of the Third "Neutralizing Antibodies Scientific Summit" meeting that took place on June 15<sup>th</sup> 2021 as the NHLBI representative.

- Served as Expert Reviewer for NCATS for RFA-TR-20-003 on 1-7-21 to "Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae". The specific applications required expertise in COVID-19, inflammation and thrombosis.

Focus on long term HLBS complications to HCT or infectious diseases

- Member of the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) task force, a trans-NIH initiative that includes over 20 NIH institutes. My contribution in the clinical spectrum working group helped developing two ROAs the [Recovery Cohort ROA](#) and the [Cores ROA](#).

-Currently collaborating with DLD, NIAID and NICHD to develop funding opportunities for "Pediatric COVID-19 and Respiratory Viral Co-infections".

-Collaborated with the NHLBI HIV team to address barriers to healthcare aiming to reduce gaps in HIV morbidity and mortality among disproportionately vulnerable group populations [NOT-HL-22-010](#).

-Led the renewal in 2016 (FY17-22) and was the PO from 2017 to April 2021 of the “Center of International Blood and Marrow Transplant (CIBMTR)” U24 funded by NCI and co-funded by NHLBI (FY17-FY22) [RFA-CA-17-031](#), and NIAID.

- Participated to the “NIH Blood and Marrow Transplant Late Effects Consensus” Working group brainstorming and conference (Led by NCI and NHLBI in June 2016). I was also a scientific member of the “Immune Dysregulation and Pathobiology” Working Group (*Biol Blood Marrow Transplant*. 2017) [NHLBI-and-NCI-discuss-blood-and-marrow-transplant-late-effects](#)

- Participated to the pulmonary complications of pediatric Hematopoietic Cell Transplantation (HCT) workshop that was a collaboration between NHLBI, NICHD and NCI <https://pubmed.ncbi.nlm.nih.gov/33058742/>

- Currently developing an initiative to renew the NHLBI secondary participation to “Data Management and Coordinating Center for Diagnostic Centers of Excellence Undiagnosed Diseases Network (UDN)” cooperative agreement.

#### Focus on Women’s Health

- Member of the NHLBI Women’s health group and member of the NHLBI Maternal Morbidity and Mortality (MMM) committee, aiming at identifying gaps and developing funding opportunities in research related to women’s health. The group collaborate with the ORWH closely; a recent example was our review of administrative Supplements for Research on Women’s Health [NOT-GM-21-018](#)

- Directed a research initiative that led to FOA development and currently funded 4 awards [RFA-HL-18-003](#) to study basic mechanisms of “Sex Hormones Induced Thrombosis in Pre-Menopausal Women”, using R61/R33 mechanism (\$17 M). Four multi PI grants have been awarded and are now in the R33 phase. All four investigative teams present their progress during an annual meeting that I organize to foster collaborations and monitor progress.

- PO for “Prevention of postpartum hemorrhage” K23 grant: identifying pregnant women at risk and determining the safe and effective use of TXA using state-of-the-art PK/PD modeling-K23. I am helping the investigator transitioning to her R01.

- PO for the Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial; this is a multi-site Phase III clinical trial in patients with menorrhagia and Von Willebrand disease.

- Performing a portfolio analysis in women and the blood diseases.

-Co-lead a trans NIH workshop on “Sex specific COVID-19 outcomes and management relevant for HLBS disorders from bench to bedside” in collaboration with the NHLBI Women’s health group that took place on June 16 and 17<sup>th</sup> 2022. This two-days’ workshop succeeded in its goal to express the need of translation basic biological discoveries into clinical applications and improving our ability to develop sex/gender specific prevention, intervention, and implementation strategies for COVID-19-related HLBS disorders.

#### Focus on Sickle cell disease

- Coordinate and organize the Sickle Cell Disease Advisory Committee (SCDAC); a professional Scientific Board that takes place once or twice per year and mandated by FACA. With the help of the Division’s Director, I set up the new board for the new members for 2021-2023/24. I choose the topics and the speakers; develop the agenda; present at the meetings and prepare the minutes that are posted online.

- PO for the REACH study-“Realizing Effectiveness Across Continents with Hydroxyurea”; this is an international multi-sites clinical trial Phase I/II Pilot Study of Hydroxyurea for Children with Sickle Cell Anemia. Assisted the PI submitting his grant renewal that was favourably scored.

- PO for SCD CARRE “Sickle Cell Disease and Cardiovascular Risk - Red cell Exchange Trial”; this is phase III domestic and international multi-sites UG3/UH3 clinical trial.

- Developing an initiative on reproductive health and Sickle cell disease

- **Led Workshops:**

- Led a workshop in transfusion medicine on “Primary and secondary outcomes in clinical trials in hemostasis” that took place in Natcher on September 23-24<sup>th</sup> 2019 ([hemostasis-clinical-trials-working-group](#)). The workshop gathered 150-200 leaders in the fields of transfusion medicine and clinical trials from the US, international experts, as well as other federal colleagues from the Department of Defense and the U.S. Food and Drug Administration. The workshop followed 18 months of conference calls organized between experts in 7 clinical areas. Manuscripts summarizing recommendations from the different subgroups have been submitted to different journals.

- **Membership in trans NHLBI and trans NIH Working Groups:** In addition to the NHLBI Women’s health working group, to ORWH for administrative Supplements for Research on Women’s Health [NOT-GM-21-018](#), I collaborate with my NHLBI colleagues with NIA on palliative care ([NOT-HL-20-737](#)), and ORIP, NIA and NIDDK on HTORR .(Human Tissue and Organ Related Research) [RFA-OD-17-001](#)

- I am collaborating on behalf of our DD with Drs. Walter Koroshetz (Director, NINDS) and Eric Green (Director, NHGRI) and other IC directors to the Undiagnosed Disease Network. I brought forward the renewal of secondary NHLBI participation to the network to Idea Forum in June 2022.

- **Medical Monitor:** Review as needed SAEs for the blood and marrow transplant clinical trials Network (BMT CTN, [BMT2](#)) hemostasis, and thrombosis trials.

<b>CLINICAL REVIEWER/EXTRAMURAL PROGRAM OFFICIAL</b>	<b>April 2012 – March 2015</b>
--	--------------------------------

*Agency for Healthcare Research and Quality, Center for Evidence and Quality Improvement; Rockville, MD*

- Served as COR II on contracts for systematic reviews within the Evidence-based Practice Center Program. Management of contract portfolios
- Clinical and operational oversight of comparative effectiveness reports prepared for clinicians, patients, and policymakers. The reports and meta-analyses synthesize the benefits and harms of different interventions and treatments published in randomized and observational studies within the portfolio of oncology and internal medicine. The completed systematic reviews included Imaging Tests for the Diagnosis and Staging of Pancreatic Adenocarcinoma; Imaging Tests for the Staging of Colorectal Cancer; Imaging Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma; Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review; and Use of Natriuretic Peptide Measurement in the Management of Heart Failure
- Management of proposals: formulated requests for proposals, organized their reviews and wrote final summaries of awards.
- Organized calls with stakeholders including patient’s advocates, physicians and professional societies to refine the key questions and provide input to the systematic reviews
- Program Officer for grants in the domain of comparative effectiveness and dissemination

<b>SCIENTIFIC REVIEW OFFICER</b>	<b>April 2010 – September 2010</b>
----------------------------------	------------------------------------

*Contract position with Division of Translational and Clinical Oncology, Center for Scientific Review, NIH; Bethesda, MD*

- Contributed to Scientific Review Officers' organizing and streamlining the extramural grant review process in order to ensure high quality reviews of research grant applications. Organized Special Emphasis Panels (SEP) with reviewer selection and preparation of summary statements.

<b>SCIENTIFIC CONSULTANT</b>	<b>September 2010 – June 2011</b>
------------------------------	-----------------------------------

*Beckman Coulter; Miami, FL*

- Provided scientific support to DC area researchers and clinicians in experimental design, analysis, and reagent selection in research and clinical applications of flow cytometry.

<b>RESEARCH FELLOW</b>
------------------------

<b>November 2005 – November 2009</b>
--------------------------------------

*National Cancer Institute; Bethesda, MD*

- Conducted independent research on the role of IL-7 on T, B and stem cell development using animal and cell culture models with special expertise in immune reconstitution.
- Provided technical expertise in stem cell isolation and characterization.
- Collaborated on Tbeta (Thymus, Brain and Testes Associated) in controlling stromal cell proliferation and regulating thymus function.

<b>ASSOCIATE PROFESSOR</b>
----------------------------

<b>October 2003 – November 2005</b>
-------------------------------------

*University of Angers School of Medicine and Blood Bank; Angers, France (MCU-PH)*

- Taught transfusion medicine and immunology to medical and graduate students as well as hematologists specializing in transfusion medicine.
- Initiated quality control of stem cell products used in transplant patients.
- Conducted translational research on the role of Jak2 mutation as an independent biomarker, in addition to clonality of hematopoiesis, in patients with Essential Thrombocythemia.

<b>FOGARTY VISITING FELLOW</b>
--------------------------------

<b>May 1999 – October 2003</b>
--------------------------------

*Experimental Immunology Branch (EIB), National Cancer Institute; Bethesda, MD*

- Studied the role of IL-7 on T cell progenitors using novel transgenic mouse model
- Determined IL-7 dosing impact on thymic function.
- Expanded flow cytometry technology, data collection and analysis to other EIB labs for their work on early thymic and bone marrow progenitors.

<b>CO-DIRECTOR</b>
--------------------

<b>November 1993 – May 1999</b>
---------------------------------

*Histocompatibility, Leukocyte and Platelet Immunology Laboratory Transfusion Center; Créteil, France*

- Supervised, coordinated and trained 11 full time staff.
- Wrote SOP, established GLP and obtained the accreditation for the laboratory from the European Federation for Immunogenetics (EFI).
- Implemented high resolution class I and II HLA, leukocytes and platelet genotyping techniques for bone marrow and solid organ transplant as well as for other indications.
- Expanded patient and donor bone marrow registries in collaboration with the national French transplant registry.
- Developed specialized techniques to screen antibodies and phenotype leukocytes and platelets of immunized patients for transfusion purposes.
- Conducted a retrospective study on unrelated bone marrow transplant performed in a single center since its establishment in 1969. All donor and recipient samples were requested (sometimes from overseas) and retested using the new high resolution HLA techniques in order to demonstrate a correlation between HLA matching (not detected with old techniques) and the patient's outcome.
- Discovered and published new HLA alleles in collaboration with other HLA laboratories.
- Instructed on the HLA system, transfusion medicine, and their clinical applications in five (5) different nursing schools.
- Taught hematologic diseases to residents and fellows in hematology.
- Conceived and conducted a translational research program resulting in development of the first positive DNA and RNA biomarkers to diagnose, assess severity and treat patients with Essential Thrombocythemia. This internationally recognized procedure is still in current use to improve patient management.

<b>ATTENDING PHYSICIAN</b>	<b>December 1992 – December 1996</b>
----------------------------	--------------------------------------

*Hematology Departments of Créteil Hospital, Bois Colombes Hospital, and Beaujon Hospital; Paris, France*

- Clinical care for outpatients one day/week

<b>CHIEF RESIDENT/ ASSISTANT PROFESSOR</b>	<b>November 1989 – November 1992</b>
--	--------------------------------------

*Hematology Departments of Xavier-Bichat School of Medicine and Beaujon Hospital; Paris, France (11/1989-11/1990) and Brest School of Medicine and*

*Morvan Hospital; Brest, France (11/1990-11/1992) Assistant-chef de Clinique*

- Provided full time clinical care of patients with hematologic diseases and those with auto or allogeneic bone marrow transplant.
- Enrolled patients in European clinical trials with informed consent. Hematologic diseases included leukemia, lymphomas, MPD, MDS, and auto and allo-transplant.
- Implemented regular meetings with the medical staff and outside collaborators to discuss patient care.
- Hematology faculty instructor for medical students
- Supervised and developed practical training in hematology to fellows, residents and medical students at the hospital.

---

EDUCATION

<b>Course</b> 9/14-10/14:	Statistical reasoning, Johns Hopkins University, Baltimore, MD (3 Credits)
<b>U.S. Medical License Examination</b> 8/11-6/14:	Step 1 and 2 Clinical Knowledge; Step 2 Clinical Skills
<b>Course</b> 7/12:	Principles of Epidemiology course, Johns Hopkins University, Baltimore, MD (5 Credits)
<b>Doctor of Philosophy</b> 1993-1997:	Biology of Blood Cells University of Paris VII-Denis Diderot and Faculty X. Bichat; <i>B. Grandchamp, Director. Ph.D. Thesis:</i> Essential Thrombocytemia: Physiopathology and Study of Clonality analysis, 1997.
<b>Masters Degree</b> 1992-1993:	Advanced Studies in Blood Cell Biology (DEA), University of Paris VII-Denis Diderot, Paris, France; <i>B. Grandchamp, Director</i>
<b>Masters Degree</b> 1990-1991:	Biological and Medical Hematology, University of Paris VII, France
<b>M.D. Degree, Resident and Fellow</b> 1985-1989:	Internal Medicine and Hematology, Medical school of Rennes, France. Medical Degree in Internal Medicine in October 1989. <b>Medical Thesis:</b> Thrombopenia Related to HIV Infection; Study of platelet lifespan and <i>in vitro</i> culture of

---



PROFESSIONAL  
TRAINING &  
OTHER  
DIPLOMAS

megakaryocytes; Prospective study on 12 patients, 1989.

**French medical license is current.**

**Medical School**  
1978-1984:

Medical School of Francois Rabelais; Tours, France. Successful completion of the first and second cycles of medical studies and admission to the fellowship program

**Completed training in “Ethical and Regulatory Aspects of Clinical Research” at the NIH in 2015**

**Completed Methodology in Clinical Research with FAES in 2015**

**Certification**  
6/2014:

Educational Commission for Foreign Medical Graduates

**Certification**  
2013

Contracting Officer Level II

**Certification**  
2012

Contracting Officer Level I

**Certification**  
1993:

Transfusion Medicine, University of Pierre and Marie Curie, Paris VI, France

**Diploma**  
1989-1991:

Subspecialty in Clinical Hematology (DES-C) University of Paris VII-Denis Diderot, France

**Certificate**  
1991:

Molecular and Cellular Biology (C2), University of Rene Descartes, Paris VI

**Diploma**  
1990:

Specialty in Internal Medicine (DES), Faculty of Medicine of Rennes, France

**State Diploma**  
1989:

Medical Thesis, State Diploma of Medical Doctor, Faculty of Medicine; Rennes, France

- 2021 NHLBI Director’s Award Program for CONNECTS/CR4 Group and NHLBI Women's Health Working Group
- 2020 **NHLBI Director’s Award Program** for Developers of Fast-response NHLBI COVID-19 FOAs
- **2017 NHLBI Group Award** of the Women's Health Working Group

AWARDS

- **2016 NHLBI Director's Award:** Partnership/Collaboration Award for exemplary collaboration and partnerships in developing and implementing a national study of Myelodysplastic Syndromes
  - **2016 NHLBI Director's Award:** Outstanding Clinical Research Award for exceptional commitment and teamwork managing the Blood and Marrow Transplant Clinical Trials Network, resulting in advancing the safety and availability of hematopoietic transplantation (HCT)
  - **Outstanding Poster Prize Award:** Thymus Workshop Meeting, Rolduc, Keyrade-Netherlands, 2007
  - **Travel Grant:** Federation of Clinical Societies (FOCIS) annual meeting, Paris-France, 2003
- 

PEER REVIEW  
PUBLICATIONS

1. Absence of Systemic Activation of Fibrinolysis May Explain the Lack of Hemostatic Benefit of Tranexamic Acid in Hypoproliferative Thrombocytopenia. Anton Ilich, Terry B. Gernsheimer, Darrell J, Triulzi, Heather Herren, Siobhan P. Brown, Lori A. Holle, Andrew T. Lucas, **Nahed El Kassar**, Alisa S. Wolberg, Susanne May, Nigel S. Key. *Submitted to Blood Advances*
2. Early Convalescent Plasma for High Risk Outpatients with Covid-19: Frederick Korley, Valerie Durkalski, Sharon Yeatts, Kevin Schulman, Robertson Davenport, Larry Dumont, **Nahed El Kassar**, Lydia Foster, Jennifer Hah, Siddhartha Jaiswal, Alesia Kaplan, Ezekiel Lowell, John McDyer, James Quinn, Darrell Triulzi, Carol Van Huysen, Valerie Stevenson, Kabir Yadav, Christopher Jones, Bory Kea, Aaron Burnett, Joshua Reynolds, Colin Geinader, Nathan Haas, David Beiser, Robert Silbergleit, William Barsan, Clifton Callaway. *New England Journal of Medicine -2021, August 18*
3. A Randomized Trial of Tranexamic Acid to Prevent Bleeding in Hematologic Malignancy: Terry B Gernsheimer, Siobhan P Brown, Darrell J Triulzi, Nigel S Key, **Nahed El Kassar**, Heather Herren, Poston N Jacqueline, Boyiadzis, Michael, Reeves N Brandi, Selukar, Subodh, Pagano Monica, Emerson Scott and Susanne May-2022, *Blood June 6*
4. Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The A-TREAT Trial; Terry Gernsheimer; Darrell Triulzi. Nigel Key, **Nahed El Kassar**, Herren H, Selukar, Subodh, Siobhan P. Brown, Susanne May. Accepted in **plenary session** at the *American Society of Hematology for Dec 2020 and Best of ASH abstract*
5. Philip C. Spinella, MD, **Nahed El Kassar, MD, PhD**, Andrew P. Cap, MD, PhD, Andrei L. Kindzelski, MD, PhD, Christopher S. Almond, MD, Alan Barkun, MD, MSc, Terry B. Gernsheimer, MD, Joshua Goldstein, MD, PhD, John B. Holcomb, MD, Alfonso Iorio, MD, PhD, Dennis M. Jensen, MD, Nigel Key, MB, ChB, Jerrold H. Levy, MD, Stephan A. Mayer, MD, Ernest E. Moore, MD, Simon J. Stanworth, MD, DPhil, Roger J. Lewis, MD, PhD, Marie E. Steiner, MD, MS, for the Hemostasis Trials Outcomes Working Group†. Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Blood Products and Agents in Patients with Bleeding. *J Trauma and Acute Care Surgery. J Trauma Acute Care Surg. 2021 Aug 1;91(2S Suppl 2):S19-S25.*

6. Tamburro, RF, Cooke, KR\*, Davies, SM, Goldfarb, S, Hagood, JS, Srinivasan, A, Steiner, ME, Stokes, D, DiFronzo, N, **El-Kassar, N**, Shelburne, N, and Natarajan, A; Pulmonary Complications of Pediatric Hematopoietic Stem Cell Transplantation (HCT)- a NIH Workshop Summary; *The Annales of the American Thoracic Society*. 2021 Mar;18(3): 381-394
7. Pablo Cure, Melania Bembea, Stella Chou, Allan Doctor, Anne Eder, Jeanne Hendrickson, Cassandra Josephson, Alan Mast, William Savage, Martha Sola-Visner, Philip Spinella, Simon Stanworth, Marie Steiner, Traci Mondoro, Shimian Zou, Catherine Levy, Myron Waclawiw, **Nahed El Kassar**, Simone Glynn and Naomi Luban 2016. Proceedings of the National Heart, Lung and Blood Institute's Scientific Priorities in Pediatric Transfusion Medicine. *Transfusion*, 2017 Jun;57(6):1568-1581
8. Gea-Banacloche J, Komanduri K, Carpenter P, Paczesny S, Sarantopoulos S, Young JA, **El Kassar N**, Le RQ, Schultz K, Griffith LM, Savani B, Wingard JR. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: the Immune Dysregulation and Pathobiology Working Group Report. *Biol Blood Marrow Transplant*. 2017 Jun;23(6):870-881
9. **El-Kassar N**, Flomerfelt F.A, Choudhury B., Hugar L.A., Chua K. S., Kappor V., Lucas P. J., Gress R.E. High levels of IL-7 cause dysregulation of thymocyte development. *International Immunology*, 2012; 24: 661-667
10. Flomerfelt F.A., **El Kassar N.**, League S.C., Schmitz S., Gurunathan C., Kapoor V., Yan X.Y., Chen C., Schwartz R. H., Gress R. E. Spatial Inhibits the Nedd8 Pathway and Modulates Thymic Function and TEC Proliferation. *Journal of Experimental Medicine*, 2010; 11: 2521-31
11. **El Kassar N.**, Gress, R.E. An overview of IL-7 and its use in immunotherapy. *Journal of Immunotoxicology*, 2010; 3: 1-7
12. Kiladjian JJ, **ElKassar N**, Cassinet B, Hetet G., Giraudier S, Balitrand N, Conejero C, Briere J, Fenaux P, Chomienne C, Grandchamp B. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. *Leukemia*, 2006; 20 :1181-3
13. **El Kassar N**, Schmidt A, Bidet ML, Ifrah N. Cytokines et épargne en transfusion. *La transfusion sanguine* demain, Edition John Libbey, 2006, 77-91
14. Munitic I, Williams JA, Yang Y, Dong B, Lucas PJ, **El Kassar N**, Gress RE, Ashwell JD. Dynamic regulation of IL-7 receptor expression is required for normal thymopoiesis. *Blood*, 2004; 104: 4165-72
15. **El Kassar N**, Lucas PJ, Klug D, Zamisch M, Merchant M, Bare CV, Choudhury B, Sharrow SO, Richie E, Mackall CL, Gress RE. A dose effect of IL-7 on thymocyte development, *Blood*, 2004; 104: 1419-1427
16. Baron C, Pastural M, Lang P, Bentabet R, **El-Kassar N**, Seror T, Dahmane D, Desvaux D, Chopin D, Fruchaud G, Remy P, Grimbert P, Lepage E, Bierling P. Long-term kidney graft survival across a positive historic but negative current sensitized cross-match. *Transplantation*, 2002; 73 (2): 232-236
17. **El Kassar N**, Le Gouvello S, Marie Joseph C, Rieux C, Cordonnier C, Vernant JP, Farcet JP, Bierling P, Kuentz M. High resolution HLA Class I and II typing and CTLp frequency in unrelated donor transplantation. *Bone Marrow Transplantation*, 2001; 27: 35-43

18. Tamouza R, **El Kassar N**, Schaeffer V, Carbonnelle E, Tatari Z, Marzais F, Fortier C, Poirier C, Sadki K, Bernaudin F, Toubert A, Krishnamoorthy R, Charron D. A novel HLA-B\*39 allele (HLA-B\*3916) due to a rare mutation causing cryptic activation. *Human Immunology*, 2000; 61: 467-473
19. Brière J, **El-Kassar N**. Clonality markers in polycythaemia and primary thrombocythaemia. *Baillieres Clinical Haematology*, 1998; 11: 787-801
20. Tamouza R, Visser C.J.T, **El Kassar N**, Poirier JC, Toubert A, Bierling P, Raffoux C, Charron D. Identification of a novel HLA-B\*51 variant: HLA-B\*5112. *Tissue Antigens*, 1998; 52: 713-7.
21. **El-Kassar N**, Hetet G, Brière J, Grandchamp B. Clonality analysis of haematopoiesis and thrombopoietin levels in patients with essential thrombocythemia. *Leukemia and lymphoma*, 1998; 30: 181-188
22. **El Kassar N**, Hetet G, Brière J, Grandchamp B. X-chromosome inactivation in normal females: incidence of excessive lyonization with age and comparison of assays using DNA methylation and those using analysis of transcript polymorphisms. *Clinical Chemistry*, 1998; 44: 61-65.
23. Kiladjian JJ, **ElKassar N**, Hetet G, Brière J, Grandchamp B, Gardin C. Study of thrombopoietin receptor in essential thrombocythemia. *Leukemia*, 1997; 11: 1821-1826.
24. **El-Kassar N**, Hetet G, Brière J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T-lymphocytes and platelets. *Blood*, 1997; 89: 128-134
25. **El-Kassar N**. Etude de la clonalité de l'hématopoïèse selon le principe de l'inactivation du chromosome X et son application dans la thrombocytémie essentielle. *Hématologie*, 1996; 2 : 531-536
26. Yan L , **ElKassar N**, Gardin C, Brière J. Clonality assays and megakaryocytes cultures techniques in essential thrombocythemia. *Leukemia and lymphoma*, 1996; 22: 31-40
27. **El Kassar N**, Kaflon P, Fromont P, Vezinet C, Godeau B, Duedari N, Bierling P. Fusidic acid-induced acute immunologic thrombocytopenia. *British journal of Haematology*, 1996; 93: 427-431
28. **El Kassar N**, Hetet G, Brière J, Grandchamp B. Clonal analysis of Haematopoietic cells in essential thrombocythemia. *British journal of Haematology*, 1995; 90: 131-137
29. Bierling P, Godeau B, Fromont P, Bettaib A, Debili N, **El Kassar N**, Rouby JJ, Vainchenker W, Duedari N. Post-transfusion purpura associated with CD36 (Nak<sup>a</sup>) isoimmunisation. *Transfusion*, 1995; 35: 777-782
30. Abgrall JF, **El Kassar N**, Berthou C, Renard I, Cauvin JM, Lepailleur A, Autrand C, Sensebe L, Guern G, Zilliken P, Le Gall G, Brière J. *In vitro* megakaryocyte colony formation in patients with idiopathic thrombopenic purpura : differences between acute and chronic ITP. *International Journal of Cell Cloning*, 1992; 10: 38-42
31. Abgrall JF, **El Kassar N**, Berthou C, Cauvin JM, Renard I, Autrand C, Zilliken P, Sensebe L, Guern G, Le Gall G, Brière J. HIV associated thrombocytopenia : megakaryocyte *in vitro* colony formation in ten patients. *Annales de Médecine Interne*, 1992; 143: 104-106